This thesis demonstrates that the integration of refined isomiR and tRF profiles within targeted liquid biopsy populations (TEPs and PD), supported by advanced bioinformatics tools like miRGalaxy, significantly enhances the accuracy and sensitivity of cancer diagnosis.
Abstract
This PhD thesis establishes a comprehensive framework for advancing non-invasive cancer diagnostics through the characterization and combinatorial analysis of small non-coding RNAs (sncRNAs), specifically microRNA isoforms (isomiRs) and tRNA-derived fragments (tRFs). Liquid biopsy offers a minimally invasive alternative to traditional tissue biopsies, allowing for real-time disease monitoring via biomolecules like circulating tumor cells, extracellular vesicles (EVs), and tumor-educated platelets (TEPs). While canonical miRNAs are established biomarkers, this work demonstrates that isomiRs (variants resulting from alternative processing) and tRFs arising from tRNA cleavage represent a richer, underutilized reservoir of disease-specific signals.
To address the significant bioinformatics challenges and lack of standardized pipelines in the field, this thesis presents miRGalaxy. miRGalaxy is a novel, open-source, Galaxy-based framework designed for interactive and in-depth sequencing data analysis, enabling researchers without extensive computational backgrounds to identify and assess the differential expression of individual isomiR species.
The clinical utility of these sncRNAs was explored through multiple omics studies. In pancreatic ductal adenocarcinoma (PDAC), multi-omics profiling of TEPs revealed profound changes in the biological repertoire, including significantly high activity in RNA splicing and mRNA processing. A key finding was the downregulation of SPARC transcripts in PDAC platelets, which was strongly correlated with negative regulation by specific isomiRs such as miR-29a-3p and miR-22-3p.
Further characterization of the small RNA landscape in non-small-cell lung cancer (NSCLC) focused on "Platelet Dust" (PD) platelet-derived extracellular vesicles. PD was found to be significantly more enriched with miRNAs (~80–82%) compared to general EVs (~66%), which are relatively more enriched in tRNAs. This highlights PD as a more informative and distinct biomarker source for distinguishing cancer patients from healthy controls.
The culmination of this research is a combinatorial analysis of miRNAs, isomiRs, and tRFs from plasma EVs in colorectal and prostate cancer. By leveraging the synergistic effects of these different RNA species, the study achieved a diagnostic accuracy and Area Under the Curve (AUC) of approximately 80%. This approach proves more effective than analyzing single RNA types in isolation, providing a robust statistical framework for improved cancer management.
In conclusion, this thesis demonstrates that the integration of refined isomiR and tRF profiles within targeted liquid biopsy populations (TEPs and PD), supported by advanced bioinformatics tools like miRGalaxy, significantly enhances the accuracy and sensitivity of cancer diagnosis. These findings pave the way for more precise preventive screening and personalized oncology.
Liquid biopsy is now an established component of precision oncology, and its clinical implementation to date has been led by cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) assays. These assays report genomic alterations, yet they may be limited by low tumor fraction, reduced shedding in early disease, and incomplete representation of dynamic tumor biology. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and emerging small or poorly annotated RNA species, provide a complementary layer because they can reflect regulatory programs, tissue injury, immune modulation, metastatic communication, and therapeutic pressure. This review explores circulating and extracellular vesicle (EV)-associated ncRNAs as functional readouts in cancer liquid biopsy. We discuss their biological origin, carrier state, biofluid context, clinical applications, analytical technologies, artificial intelligence (AI)-assisted integration, standardization barriers, and regulatory requirements. The technology discussion considers sequencing, targeted amplification, and emerging direct or polymerase chain reaction (PCR)-free strategies as complementary translational routes for reliable ncRNA measurement. We propose that ncRNAs should not be viewed as alternatives to ctDNA, but as potential functional biomarkers that can link tumor genotype, regulatory state, and clinical phenotype within integrated multi-analyte precision oncology.
It is proposed that the upregulated lncRNA ENSG00000265613 may enhance malignancy by stabilizing the RNA target ENSG00000582008 in luminal A breast cancer, particularly given its established role in oncogenesis.
C. Guda, Sankarasubramanian Jagadesan, Avinash M. Veerappa· Methods in molecular biology· 0 citations
Much of the apparent cmDNA structure, including its agreement with a published cancer-microbiome catalog, is explained by base composition and reference-database architecture rather than authentic biology, and short-read k-mer pipelines cannot separate the two on their own.
Daisy Fry Brumit, Daniel Bsteh, Shan Sun et al.· bioRxiv· 0 citations
CircRNAs are covalently closed ncRNAs originating through back splicing; their expression is finely regulated, displaying specific patterns across different cell types, tissues, and developmental stages. While the molecular functions of circRNAs are not completely elucidated, their regulatory involvement in physiological processes is well established, alongside their dysregulation in several human disorders. These features, together with their higher stability compared to other ncRNAs, make this class of molecules promising theragnostic agents, particularly in biomarker discovery. Accordingly, it is crucial to develop and standardize experimental strategies that improve circRNA analysis, ensuring accurate and effective isolation of these molecules. In biomarker discovery, selecting the appropriate biological matrix is critical; whole blood is often preferred for its accessibility and minimally invasive collection. Because circRNAs are present in human peripheral blood and show promise as disease theragnostic biomarkers, we established a preliminary workflow tailored to isolate and analyze circRNAs from whole blood. The promising effectiveness and robustness of this workflow were demonstrated by qPCR analysis, suggesting highly reproducible detection and reliability in isolating and analyzing circRNAs. This, together with their stability and specific expression profiles, supports the utility of circRNAs in biomarker discovery and advanced circRNA research and contributes to accelerating their future integration into theragnostic applications in clinical settings.
Federica Cieri, V. Valsecchi, Lorenzo d'Amico di S Domenico et al.· Biomolecules· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.